| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Megakaryoblastic, Acute | 2 | 2022 | 47 | 1.590 |
Why?
|
| Proto-Oncogene Proteins B-raf | 7 | 2017 | 1283 | 1.220 |
Why?
|
| Biomarkers, Tumor | 11 | 2023 | 10331 | 0.850 |
Why?
|
| Blood Platelet Disorders | 1 | 2022 | 37 | 0.820 |
Why?
|
| Carcinoma, Papillary | 2 | 2013 | 584 | 0.690 |
Why?
|
| Melanoma | 6 | 2016 | 5317 | 0.690 |
Why?
|
| Sarcoma, Myeloid | 1 | 2019 | 95 | 0.670 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2022 | 387 | 0.620 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2022 | 489 | 0.620 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 328 | 0.610 |
Why?
|
| Mediastinal Neoplasms | 1 | 2020 | 423 | 0.570 |
Why?
|
| Testicular Neoplasms | 1 | 2020 | 529 | 0.560 |
Why?
|
| Carcinoma, Small Cell | 1 | 2018 | 408 | 0.540 |
Why?
|
| Thyroid Neoplasms | 3 | 2018 | 1866 | 0.520 |
Why?
|
| Mutation | 15 | 2023 | 15179 | 0.490 |
Why?
|
| Genetic Techniques | 1 | 2014 | 130 | 0.470 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 1331 | 0.470 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2014 | 164 | 0.430 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 1664 | 0.410 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 600 | 0.370 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2023 | 2291 | 0.370 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2022 | 755 | 0.360 |
Why?
|
| Skin Neoplasms | 3 | 2015 | 4654 | 0.360 |
Why?
|
| Hepatoblastoma | 2 | 2022 | 215 | 0.350 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2016 | 5319 | 0.340 |
Why?
|
| ErbB Receptors | 2 | 2016 | 2295 | 0.320 |
Why?
|
| Genetic Testing | 2 | 2019 | 1589 | 0.300 |
Why?
|
| Molecular Targeted Therapy | 2 | 2014 | 2330 | 0.300 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2006 | 18 | 0.300 |
Why?
|
| Humans | 43 | 2023 | 261506 | 0.280 |
Why?
|
| Ovarian Neoplasms | 2 | 2022 | 4638 | 0.280 |
Why?
|
| Child | 13 | 2023 | 29154 | 0.270 |
Why?
|
| GTP-Binding Proteins | 1 | 2006 | 321 | 0.260 |
Why?
|
| Repressor Proteins | 3 | 2022 | 1664 | 0.260 |
Why?
|
| Genomics | 2 | 2021 | 2738 | 0.250 |
Why?
|
| Transcriptome | 1 | 2013 | 1859 | 0.250 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 3022 | 0.240 |
Why?
|
| Lung Neoplasms | 3 | 2016 | 11538 | 0.240 |
Why?
|
| Neoplasms | 4 | 2022 | 15193 | 0.240 |
Why?
|
| Immunohistochemistry | 8 | 2017 | 7548 | 0.240 |
Why?
|
| Quality Control | 2 | 2016 | 457 | 0.230 |
Why?
|
| Extracellular Matrix | 1 | 2006 | 554 | 0.230 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 1870 | 0.220 |
Why?
|
| Lipids | 1 | 2006 | 644 | 0.220 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2022 | 19 | 0.210 |
Why?
|
| Fibroma | 1 | 2022 | 85 | 0.210 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 6915 | 0.210 |
Why?
|
| Endonucleases | 2 | 2013 | 178 | 0.210 |
Why?
|
| Carcinoma | 1 | 2013 | 2578 | 0.200 |
Why?
|
| Sequence Analysis, DNA | 4 | 2022 | 2483 | 0.200 |
Why?
|
| DNA Mutational Analysis | 3 | 2019 | 2283 | 0.200 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 2326 | 0.190 |
Why?
|
| Ribonuclease III | 1 | 2022 | 182 | 0.190 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2022 | 217 | 0.190 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 235 | 0.180 |
Why?
|
| Adolescent | 10 | 2022 | 31252 | 0.180 |
Why?
|
| Brain Neoplasms | 3 | 2023 | 4849 | 0.180 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 255 | 0.180 |
Why?
|
| Cyclin B | 1 | 2019 | 63 | 0.180 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 4971 | 0.180 |
Why?
|
| DNA Polymerase II | 1 | 2019 | 59 | 0.180 |
Why?
|
| Ligands | 1 | 2022 | 995 | 0.180 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2019 | 41 | 0.180 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 109 | 0.170 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2019 | 35 | 0.170 |
Why?
|
| Hemangiosarcoma | 1 | 2022 | 234 | 0.170 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 1 | 2019 | 33 | 0.170 |
Why?
|
| Chernobyl Nuclear Accident | 1 | 2018 | 12 | 0.170 |
Why?
|
| Ependymoma | 1 | 2021 | 242 | 0.170 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 568 | 0.160 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 197 | 0.160 |
Why?
|
| Granulosa Cell Tumor | 1 | 2018 | 77 | 0.160 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 661 | 0.160 |
Why?
|
| Codon, Nonsense | 1 | 2018 | 164 | 0.160 |
Why?
|
| Herpesvirus 4, Human | 1 | 2022 | 966 | 0.160 |
Why?
|
| Radiation Exposure | 1 | 2018 | 73 | 0.150 |
Why?
|
| Hypercalcemia | 1 | 2018 | 137 | 0.150 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2022 | 607 | 0.150 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2019 | 221 | 0.150 |
Why?
|
| Pyridazines | 1 | 2019 | 293 | 0.140 |
Why?
|
| Loss of Heterozygosity | 1 | 2018 | 602 | 0.140 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 502 | 0.140 |
Why?
|
| Transcription Factors | 2 | 2022 | 5270 | 0.140 |
Why?
|
| Thrombocytosis | 1 | 2017 | 121 | 0.140 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 49 | 0.140 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2016 | 82 | 0.140 |
Why?
|
| Limit of Detection | 1 | 2016 | 78 | 0.140 |
Why?
|
| DNA Helicases | 1 | 2018 | 434 | 0.140 |
Why?
|
| Oxo-Acid-Lyases | 1 | 2015 | 3 | 0.140 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2015 | 10 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2015 | 8873 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 1048 | 0.130 |
Why?
|
| Gene Rearrangement | 2 | 2020 | 783 | 0.130 |
Why?
|
| Calreticulin | 1 | 2015 | 74 | 0.130 |
Why?
|
| Heterozygote | 1 | 2018 | 1020 | 0.130 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 1022 | 0.130 |
Why?
|
| Liver Neoplasms | 2 | 2022 | 4557 | 0.130 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 226 | 0.130 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 882 | 0.130 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 1516 | 0.130 |
Why?
|
| Receptor, ErbB-2 | 2 | 2016 | 2518 | 0.130 |
Why?
|
| Male | 16 | 2021 | 123000 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2018 | 3552 | 0.130 |
Why?
|
| Lymphoma, B-Cell | 1 | 2021 | 895 | 0.120 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2015 | 132 | 0.120 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2015 | 160 | 0.120 |
Why?
|
| Ovary | 1 | 2018 | 668 | 0.120 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2015 | 115 | 0.120 |
Why?
|
| Medulloblastoma | 1 | 2019 | 540 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2022 | 2488 | 0.120 |
Why?
|
| Female | 17 | 2022 | 141928 | 0.120 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2017 | 261 | 0.120 |
Why?
|
| Imidazoles | 1 | 2019 | 999 | 0.120 |
Why?
|
| Thymidylate Synthase | 1 | 2013 | 53 | 0.110 |
Why?
|
| Lipoma | 1 | 2013 | 89 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2016 | 2232 | 0.110 |
Why?
|
| Azacitidine | 1 | 2019 | 1149 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 1299 | 0.110 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2014 | 203 | 0.110 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2012 | 16 | 0.110 |
Why?
|
| Survivors | 1 | 2018 | 1031 | 0.110 |
Why?
|
| Hodgkin Disease | 1 | 2021 | 1429 | 0.110 |
Why?
|
| Pyrazoles | 1 | 2021 | 1471 | 0.110 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2012 | 29 | 0.110 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2018 | 716 | 0.110 |
Why?
|
| DNA-Binding Proteins | 3 | 2019 | 4821 | 0.110 |
Why?
|
| DNA Primers | 1 | 2014 | 1399 | 0.100 |
Why?
|
| Sarcoma | 1 | 2022 | 1725 | 0.100 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 486 | 0.100 |
Why?
|
| Leukemia | 1 | 2020 | 1635 | 0.100 |
Why?
|
| Specialties, Surgical | 1 | 2013 | 137 | 0.100 |
Why?
|
| Adenocarcinoma | 3 | 2014 | 7789 | 0.100 |
Why?
|
| Stomach Neoplasms | 2 | 2013 | 2278 | 0.090 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2012 | 167 | 0.090 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2012 | 334 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 2027 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1217 | 0.090 |
Why?
|
| Infant | 3 | 2019 | 13310 | 0.090 |
Why?
|
| Exons | 1 | 2013 | 1328 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2014 | 1152 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2021 | 3518 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2019 | 16273 | 0.080 |
Why?
|
| Myeloproliferative Disorders | 1 | 2015 | 767 | 0.080 |
Why?
|
| Prognosis | 6 | 2019 | 21713 | 0.080 |
Why?
|
| Apoptosis | 1 | 2022 | 7591 | 0.080 |
Why?
|
| Base Sequence | 1 | 2014 | 4917 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 6009 | 0.080 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2006 | 10 | 0.070 |
Why?
|
| Cholangiocarcinoma | 1 | 2012 | 493 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 3343 | 0.070 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2006 | 42 | 0.070 |
Why?
|
| Sphingosine | 1 | 2006 | 55 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 3 | 2013 | 3981 | 0.070 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2006 | 80 | 0.070 |
Why?
|
| Endometrial Neoplasms | 1 | 2016 | 1341 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 5159 | 0.070 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2006 | 107 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 1 | 2006 | 143 | 0.070 |
Why?
|
| Lysophospholipids | 1 | 2006 | 147 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 2796 | 0.070 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 2527 | 0.070 |
Why?
|
| Young Adult | 4 | 2022 | 21445 | 0.060 |
Why?
|
| Aged | 7 | 2016 | 70117 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2013 | 1423 | 0.060 |
Why?
|
| Adult | 7 | 2018 | 77950 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 5061 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 1823 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 10035 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 3578 | 0.060 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 1046 | 0.060 |
Why?
|
| Middle Aged | 7 | 2016 | 86204 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2015 | 11965 | 0.060 |
Why?
|
| Collagen | 1 | 2006 | 752 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 29902 | 0.050 |
Why?
|
| Receptor, trkB | 1 | 2021 | 53 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2022 | 272 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2006 | 2216 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 5395 | 0.040 |
Why?
|
| Cell Movement | 1 | 2006 | 2466 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2021 | 436 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia Type 2b | 1 | 2018 | 53 | 0.040 |
Why?
|
| Pancreas | 1 | 2022 | 718 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2019 | 234 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2018 | 115 | 0.040 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2022 | 690 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 2292 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 268 | 0.040 |
Why?
|
| Models, Biological | 1 | 2006 | 3254 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2022 | 652 | 0.040 |
Why?
|
| Germ Cells | 1 | 2019 | 335 | 0.040 |
Why?
|
| Leukocytosis | 1 | 2017 | 112 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 1073 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 8865 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2018 | 370 | 0.030 |
Why?
|
| Acetoacetates | 1 | 2015 | 20 | 0.030 |
Why?
|
| Pathology, Surgical | 1 | 2016 | 81 | 0.030 |
Why?
|
| Polyps | 1 | 2016 | 74 | 0.030 |
Why?
|
| Cerebellar Neoplasms | 1 | 2019 | 434 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2019 | 779 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2022 | 1960 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2019 | 1005 | 0.030 |
Why?
|
| Pelvis | 1 | 2016 | 362 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 2015 | 259 | 0.030 |
Why?
|
| Neoplasms, Adipose Tissue | 1 | 2013 | 10 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 4988 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2022 | 14551 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 4844 | 0.030 |
Why?
|
| Remission Induction | 1 | 2019 | 3569 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 6207 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 644 | 0.030 |
Why?
|
| Time Factors | 1 | 2006 | 12926 | 0.030 |
Why?
|
| Endometrium | 1 | 2016 | 470 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 10001 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2016 | 9244 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 14289 | 0.030 |
Why?
|
| Uterus | 1 | 2016 | 678 | 0.020 |
Why?
|
| Recurrence | 1 | 2019 | 4758 | 0.020 |
Why?
|
| Algorithms | 1 | 2022 | 3890 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2013 | 583 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 703 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 7222 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 2450 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 2307 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 1742 | 0.020 |
Why?
|
| Phenotype | 1 | 2019 | 6295 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2013 | 899 | 0.020 |
Why?
|
| Genotype | 1 | 2015 | 4109 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 4320 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 5539 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 3260 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 4892 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 4744 | 0.010 |
Why?
|
| Mice | 1 | 2022 | 34495 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 14889 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2013 | 37905 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2013 | 5542 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 15862 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 59536 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2012 | 12873 | 0.010 |
Why?
|